CGEM

SEC source: 0000899243-23-005732 · doc4.xml · derivative · entry 2

SUMER JACQUELYN L · CIK 0001844824 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,500

Underlying: Common Stock · 93,500 shares

Expires 2033-02-16

F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

SEC source: 0000899243-23-005732 · doc4.xml · nonDerivative · entry 1

SUMER JACQUELYN L · CIK 0001844824 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,000

F1 · shares: The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

SEC source: 0000899243-23-005729 · doc4.xml · derivative · entry 2

Michaelson Jennifer · CIK 0001838061 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,000

Underlying: Common Stock · 77,000 shares

Expires 2033-02-16

F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

SEC source: 0000899243-23-005729 · doc4.xml · nonDerivative · entry 1

Michaelson Jennifer · CIK 0001838061 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,531

F1 · shares: The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

SEC source: 0000899243-23-005728 · doc4.xml · derivative · entry 2

Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2033-02-16

F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

SEC source: 0000899243-23-005728 · doc4.xml · nonDerivative · entry 1

Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

F1 · shares: The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

SEC source: 0000921895-23-000144 · form407422cgem_01192023.xml · derivative · entry 6

BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner

BVF INC/IL · CIK 0001056807 · 10% owner

LAMPERT MARK N · CIK 0001233840 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 300,000 shares

Expires not disclosed

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F6 · derivative.exercise_price: The Series A Preferred Stock is convertible at any time at the option of the holder into a number of shares of Common Stock equal to the Conversion Ratio equal to a Stated Value of $109.20 per share divided by a Conversion Price of $10.92, or 10 shares of Common Stock for each share of Series A Preferred Stock, subject to adjustment as provided in the Certificate of Designations for the Series A Preferred Stock (the "COD"). Under the COD, the Series A Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock pursuant to such conversion. The Series A Preferred Stock has no expiration date.

F5 · kind: Pursuant to a letter agreement with the Issuer, BVF, BVF2 and Trading Fund OS agreed to exchange an aggregate of 6,400,000 shares of Common Stock for a total of 640,000 shares of newly issued Series A Convertible Preferred Stock (the "Series A Preferred Stock") as set forth herein.

F6 · price: The Series A Preferred Stock is convertible at any time at the option of the holder into a number of shares of Common Stock equal to the Conversion Ratio equal to a Stated Value of $109.20 per share divided by a Conversion Price of $10.92, or 10 shares of Common Stock for each share of Series A Preferred Stock, subject to adjustment as provided in the Certificate of Designations for the Series A Preferred Stock (the "COD"). Under the COD, the Series A Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock pursuant to such conversion. The Series A Preferred Stock has no expiration date.

F6 · derivative.exercise_date: The Series A Preferred Stock is convertible at any time at the option of the holder into a number of shares of Common Stock equal to the Conversion Ratio equal to a Stated Value of $109.20 per share divided by a Conversion Price of $10.92, or 10 shares of Common Stock for each share of Series A Preferred Stock, subject to adjustment as provided in the Certificate of Designations for the Series A Preferred Stock (the "COD"). Under the COD, the Series A Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock pursuant to such conversion. The Series A Preferred Stock has no expiration date.

F6 · derivative.expiration_date: The Series A Preferred Stock is convertible at any time at the option of the holder into a number of shares of Common Stock equal to the Conversion Ratio equal to a Stated Value of $109.20 per share divided by a Conversion Price of $10.92, or 10 shares of Common Stock for each share of Series A Preferred Stock, subject to adjustment as provided in the Certificate of Designations for the Series A Preferred Stock (the "COD"). Under the COD, the Series A Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock pursuant to such conversion. The Series A Preferred Stock has no expiration date.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0000921895-23-000144 · form407422cgem_01192023.xml · derivative · entry 5

BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner

BVF INC/IL · CIK 0001056807 · 10% owner

LAMPERT MARK N · CIK 0001233840 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 260,000

Underlying: Common Stock · 2,600,000 shares

Expires not disclosed

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F6 · derivative.exercise_price: The Series A Preferred Stock is convertible at any time at the option of the holder into a number of shares of Common Stock equal to the Conversion Ratio equal to a Stated Value of $109.20 per share divided by a Conversion Price of $10.92, or 10 shares of Common Stock for each share of Series A Preferred Stock, subject to adjustment as provided in the Certificate of Designations for the Series A Preferred Stock (the "COD"). Under the COD, the Series A Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock pursuant to such conversion. The Series A Preferred Stock has no expiration date.

F5 · kind: Pursuant to a letter agreement with the Issuer, BVF, BVF2 and Trading Fund OS agreed to exchange an aggregate of 6,400,000 shares of Common Stock for a total of 640,000 shares of newly issued Series A Convertible Preferred Stock (the "Series A Preferred Stock") as set forth herein.

F6 · price: The Series A Preferred Stock is convertible at any time at the option of the holder into a number of shares of Common Stock equal to the Conversion Ratio equal to a Stated Value of $109.20 per share divided by a Conversion Price of $10.92, or 10 shares of Common Stock for each share of Series A Preferred Stock, subject to adjustment as provided in the Certificate of Designations for the Series A Preferred Stock (the "COD"). Under the COD, the Series A Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock pursuant to such conversion. The Series A Preferred Stock has no expiration date.

F6 · derivative.exercise_date: The Series A Preferred Stock is convertible at any time at the option of the holder into a number of shares of Common Stock equal to the Conversion Ratio equal to a Stated Value of $109.20 per share divided by a Conversion Price of $10.92, or 10 shares of Common Stock for each share of Series A Preferred Stock, subject to adjustment as provided in the Certificate of Designations for the Series A Preferred Stock (the "COD"). Under the COD, the Series A Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock pursuant to such conversion. The Series A Preferred Stock has no expiration date.

F6 · derivative.expiration_date: The Series A Preferred Stock is convertible at any time at the option of the holder into a number of shares of Common Stock equal to the Conversion Ratio equal to a Stated Value of $109.20 per share divided by a Conversion Price of $10.92, or 10 shares of Common Stock for each share of Series A Preferred Stock, subject to adjustment as provided in the Certificate of Designations for the Series A Preferred Stock (the "COD"). Under the COD, the Series A Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock pursuant to such conversion. The Series A Preferred Stock has no expiration date.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0000921895-23-000144 · form407422cgem_01192023.xml · derivative · entry 4

BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner

BVF INC/IL · CIK 0001056807 · 10% owner

LAMPERT MARK N · CIK 0001233840 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 3,500,000 shares

Expires not disclosed

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F6 · derivative.exercise_price: The Series A Preferred Stock is convertible at any time at the option of the holder into a number of shares of Common Stock equal to the Conversion Ratio equal to a Stated Value of $109.20 per share divided by a Conversion Price of $10.92, or 10 shares of Common Stock for each share of Series A Preferred Stock, subject to adjustment as provided in the Certificate of Designations for the Series A Preferred Stock (the "COD"). Under the COD, the Series A Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock pursuant to such conversion. The Series A Preferred Stock has no expiration date.

F5 · kind: Pursuant to a letter agreement with the Issuer, BVF, BVF2 and Trading Fund OS agreed to exchange an aggregate of 6,400,000 shares of Common Stock for a total of 640,000 shares of newly issued Series A Convertible Preferred Stock (the "Series A Preferred Stock") as set forth herein.

F6 · price: The Series A Preferred Stock is convertible at any time at the option of the holder into a number of shares of Common Stock equal to the Conversion Ratio equal to a Stated Value of $109.20 per share divided by a Conversion Price of $10.92, or 10 shares of Common Stock for each share of Series A Preferred Stock, subject to adjustment as provided in the Certificate of Designations for the Series A Preferred Stock (the "COD"). Under the COD, the Series A Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock pursuant to such conversion. The Series A Preferred Stock has no expiration date.

F6 · derivative.exercise_date: The Series A Preferred Stock is convertible at any time at the option of the holder into a number of shares of Common Stock equal to the Conversion Ratio equal to a Stated Value of $109.20 per share divided by a Conversion Price of $10.92, or 10 shares of Common Stock for each share of Series A Preferred Stock, subject to adjustment as provided in the Certificate of Designations for the Series A Preferred Stock (the "COD"). Under the COD, the Series A Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock pursuant to such conversion. The Series A Preferred Stock has no expiration date.

F6 · derivative.expiration_date: The Series A Preferred Stock is convertible at any time at the option of the holder into a number of shares of Common Stock equal to the Conversion Ratio equal to a Stated Value of $109.20 per share divided by a Conversion Price of $10.92, or 10 shares of Common Stock for each share of Series A Preferred Stock, subject to adjustment as provided in the Certificate of Designations for the Series A Preferred Stock (the "COD"). Under the COD, the Series A Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock pursuant to such conversion. The Series A Preferred Stock has no expiration date.

F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0000921895-23-000144 · form407422cgem_01192023.xml · nonDerivative · entry 3

BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner

BVF INC/IL · CIK 0001056807 · 10% owner

LAMPERT MARK N · CIK 0001233840 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,161

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F5 · kind: Pursuant to a letter agreement with the Issuer, BVF, BVF2 and Trading Fund OS agreed to exchange an aggregate of 6,400,000 shares of Common Stock for a total of 640,000 shares of newly issued Series A Convertible Preferred Stock (the "Series A Preferred Stock") as set forth herein.

F6 · price: The Series A Preferred Stock is convertible at any time at the option of the holder into a number of shares of Common Stock equal to the Conversion Ratio equal to a Stated Value of $109.20 per share divided by a Conversion Price of $10.92, or 10 shares of Common Stock for each share of Series A Preferred Stock, subject to adjustment as provided in the Certificate of Designations for the Series A Preferred Stock (the "COD"). Under the COD, the Series A Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock pursuant to such conversion. The Series A Preferred Stock has no expiration date.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0000921895-23-000144 · form407422cgem_01192023.xml · nonDerivative · entry 2

BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner

BVF INC/IL · CIK 0001056807 · 10% owner

LAMPERT MARK N · CIK 0001233840 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 392,808

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F5 · kind: Pursuant to a letter agreement with the Issuer, BVF, BVF2 and Trading Fund OS agreed to exchange an aggregate of 6,400,000 shares of Common Stock for a total of 640,000 shares of newly issued Series A Convertible Preferred Stock (the "Series A Preferred Stock") as set forth herein.

F6 · price: The Series A Preferred Stock is convertible at any time at the option of the holder into a number of shares of Common Stock equal to the Conversion Ratio equal to a Stated Value of $109.20 per share divided by a Conversion Price of $10.92, or 10 shares of Common Stock for each share of Series A Preferred Stock, subject to adjustment as provided in the Certificate of Designations for the Series A Preferred Stock (the "COD"). Under the COD, the Series A Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock pursuant to such conversion. The Series A Preferred Stock has no expiration date.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0000921895-23-000144 · form407422cgem_01192023.xml · nonDerivative · entry 1

BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner

BVF INC/IL · CIK 0001056807 · 10% owner

LAMPERT MARK N · CIK 0001233840 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 558,854

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F5 · kind: Pursuant to a letter agreement with the Issuer, BVF, BVF2 and Trading Fund OS agreed to exchange an aggregate of 6,400,000 shares of Common Stock for a total of 640,000 shares of newly issued Series A Convertible Preferred Stock (the "Series A Preferred Stock") as set forth herein.

F6 · price: The Series A Preferred Stock is convertible at any time at the option of the holder into a number of shares of Common Stock equal to the Conversion Ratio equal to a Stated Value of $109.20 per share divided by a Conversion Price of $10.92, or 10 shares of Common Stock for each share of Series A Preferred Stock, subject to adjustment as provided in the Certificate of Designations for the Series A Preferred Stock (the "COD"). Under the COD, the Series A Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock pursuant to such conversion. The Series A Preferred Stock has no expiration date.

F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0000899243-23-001157 · doc4.xml · nonDerivative · entry 1

Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,402

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of July 1, 2022 through December 30, 2022. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on December 30, 2022.

SEC source: 0000899243-22-037126 · doc4.xml · derivative · entry 3

Michaelson Jennifer · CIK 0001838061 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,593

Underlying: Common Stock · 4,000 shares

Expires 2030-10-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0000899243-22-037126 · doc4.xml · nonDerivative · entry 2

Michaelson Jennifer · CIK 0001838061 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,031

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021, as amended on June 24, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.96 to $13.48. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-22-037126 · doc4.xml · nonDerivative · entry 1

Michaelson Jennifer · CIK 0001838061 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,031

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-22-034765 · doc4.xml · derivative · entry 1

Ryan David P. · CIK 0001951490 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,150

Underlying: Common Stock · 26,150 shares

Expires 2032-10-31

F1 · derivative.exercise_date: The option represents a right to purchase a total of 26,150 shares of the Issuer's Common Stock, which shall vest as to one-third of the shares underlying the option on each of the first, second and third anniversaries of the grant date of the award, subject to the Reporting Person's continued service as a director on each such vesting date.

SEC source: 0000899243-22-032236 · doc4.xml · derivative · entry 3

Michaelson Jennifer · CIK 0001838061 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 204,593

Underlying: Common Stock · 4,000 shares

Expires 2030-10-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0000899243-22-032236 · doc4.xml · nonDerivative · entry 2

Michaelson Jennifer · CIK 0001838061 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,031

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021, as amended on June 24, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.30 to $12.56. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-22-032236 · doc4.xml · nonDerivative · entry 1

Michaelson Jennifer · CIK 0001838061 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,031

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-22-028821 · doc4.xml · derivative · entry 1

SUMER JACQUELYN L · CIK 0001844824 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,000

Underlying: Common Stock · 190,000 shares

Expires 2032-08-14

F1 · derivative.exercise_date: The option represents a right to purchase a total of 190,000 shares of the Issuer's Common Stock, 25% of which will become fully vested and exercisable on August 15, 2023, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

SEC source: 0000899243-22-028132 · doc4.xml · derivative · entry 3

Michaelson Jennifer · CIK 0001838061 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 208,593

Underlying: Common Stock · 1,385 shares

Expires 2030-10-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0000899243-22-028132 · doc4.xml · nonDerivative · entry 2

Michaelson Jennifer · CIK 0001838061 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,031

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021, as amended on June 24, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.04. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-22-028132 · doc4.xml · nonDerivative · entry 1

Michaelson Jennifer · CIK 0001838061 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,416

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-22-086343 · tm2222660-1_4seq1.xml · nonDerivative · entry 3

F2 Vision SCS · CIK 0001838409 · 10% owner

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,255,963

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.56, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.direct: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001104659-22-086343 · tm2222660-1_4seq1.xml · nonDerivative · entry 2

F2 Vision SCS · CIK 0001838409 · 10% owner

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,281,952

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.direct: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001104659-22-086343 · tm2222660-1_4seq1.xml · nonDerivative · entry 1

F2 Vision SCS · CIK 0001838409 · 10% owner

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,301,081

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 to $14.17, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.direct: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-22-026737 · doc4.xml · derivative · entry 3

Michaelson Jennifer · CIK 0001838061 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 209,978

Underlying: Common Stock · 8,000 shares

Expires 2030-10-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0000899243-22-026737 · doc4.xml · nonDerivative · entry 2

Michaelson Jennifer · CIK 0001838061 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,031

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021, as amended on June 24, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.14 to $14.76. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-22-026737 · doc4.xml · nonDerivative · entry 1

Michaelson Jennifer · CIK 0001838061 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,031

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-22-026470 · doc4.xml · nonDerivative · entry 2

Savill Corrine · CIK 0001837524 · Acting Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,615

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 9, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.40. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-22-026470 · doc4.xml · nonDerivative · entry 1

Savill Corrine · CIK 0001837524 · Acting Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,573

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 9, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.16. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-22-025971 · doc4.xml · nonDerivative · entry 2

Savill Corrine · CIK 0001837524 · Acting Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,615

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 9, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.84 to $13.85. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-22-025971 · doc4.xml · nonDerivative · entry 1

Savill Corrine · CIK 0001837524 · Acting Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,815

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 9, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.82 to $13.72. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-22-025082 · doc4.xml · nonDerivative · entry 1

Michaelson Jennifer · CIK 0001838061 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,031

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of January 1, 2022 through June 30, 2022. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2022.

SEC source: 0000899243-22-025077 · doc4.xml · nonDerivative · entry 1

AHMED NADIM · CIK 0001731193 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,710

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of January 1, 2022 through June 30, 2022. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2022.

SEC source: 0000899243-22-025080 · doc4.xml · nonDerivative · entry 1

Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,201

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of January 1, 2022 through June 30, 2022. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2022.

SEC source: 0001104659-22-075392 · tm2219571-1_4seq1.xml · derivative · entry 13

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,529 shares

Expires 2022-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof.

SEC source: 0001104659-22-075392 · tm2219571-1_4seq1.xml · derivative · entry 12

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 104,845 shares

Expires 2022-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof.

SEC source: 0001104659-22-075392 · tm2219571-1_4seq1.xml · nonDerivative · entry 3

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,803

F1 · kind: Represents a net exercise of outstanding stock options. These shares were resold to the Issuer as payment of the exercise price, based on the closing price of the Issuer's common stock on June 24, 2022 of $13.39 per share.

SEC source: 0001104659-22-075392 · tm2219571-1_4seq1.xml · nonDerivative · entry 2

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 252,881

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-22-075392 · tm2219571-1_4seq1.xml · nonDerivative · entry 1

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,352

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-22-073980 · tm2219298-1_4seq1.xml · nonDerivative · entry 3

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 537,392

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.72 to $13.35, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.direct: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways Holdings Limited ("Globeways") is the appointed manager of F2 Bioscience 2017. Dr. Morana Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-22-023771 · doc4.xml · derivative · entry 1

GADICKE ANSBERT · CIK 0001134655 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,475

Underlying: Common Stock · 16,475 shares

Expires 2032-06-21

F1 · derivative.exercise_date: The option represents a right to purchase a total of 16,475 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 22, 2023 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.

SEC source: 0000899243-22-023767 · doc4.xml · derivative · entry 1

Rosenberg Anthony · CIK 0001466175 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,475

Underlying: Common Stock · 16,475 shares

Expires 2032-06-21

F1 · derivative.exercise_date: The option represents a right to purchase a total of 16,475 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 22, 2023 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.

SEC source: 0000899243-22-023769 · doc4.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,475

Underlying: Common Stock · 16,475 shares

Expires 2032-06-21

F1 · derivative.exercise_date: The option represents a right to purchase a total of 16,475 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 22, 2023 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.

SEC source: 0000899243-22-023773 · doc4.xml · derivative · entry 1

Ebeling Thomas · CIK 0001297759 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,475

Underlying: Common Stock · 16,475 shares

Expires 2032-06-21

F1 · derivative.exercise_date: The option represents a right to purchase a total of 16,475 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 22, 2023 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.

SEC source: 0001104659-22-073980 · tm2219298-1_4seq1.xml · nonDerivative · entry 2

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 567,023

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.35 to $12.92, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.direct: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways Holdings Limited ("Globeways") is the appointed manager of F2 Bioscience 2017. Dr. Morana Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001104659-22-073980 · tm2219298-1_4seq1.xml · nonDerivative · entry 1

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 616,976

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.58 to $12.99, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.direct: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways Holdings Limited ("Globeways") is the appointed manager of F2 Bioscience 2017. Dr. Morana Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-22-021346 · doc4.xml · nonDerivative · entry 1

AHMED NADIM · CIK 0001731193 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,090

F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $12.34 to $12.45. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.